9 April 2025 - The MHRA has today approved trastuzumab deruxtecan (Enhertu) to treat people with solid tumours that have mutations in human epidermal growth factor 2 (known as HER2 positive cancers) that have spread to other parts of the body (metastatic disease) or cannot be removed by surgery (unresectable), and who have no alternative treatment options.

This approval is an extension to the indication of the medicine, which has previously been approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancers, who have received two or more prior anti-HER2-based regimens for non-small cell lung cancer with an activating HER2 mutation and HER2-positive gastric cancer.

Read UK Government press release